IASIS PHARMA is pleased to announce the RosuZet® launching, in the formulation of film-coated tablets. RosuZet® is the fixed dose combination of Rosuvastatin - Ezetimibe, two active ingredients that reduce serum lipid levels with complementary mechanisms of action. Pharmacotherapeutic Class: Lipid Modifying Agents, HMG CoA reductase inhibitors in combination with other lipid modifying agents. RosuZet® [...]
IASIS PHARMA is pleased to announce the launch of the new Zylapour® 100 mg x 100 tabs package, which expands the existing Zylapour® 100 mg x 30 tabs & Zylapour® 300 mg x 30 packages. The active substance of Zylapour® is Allopurinol. Allopurinol is in the class of medications called xanthine oxidase inhibitors and it was approved for medical [...]
Launching the new Chios Mastiha in Powder (package of 15 sachets) expands the well-established Mastiha var.Chia brand. Dr. Christos Kon. Zavos, Gastroenterologist – Hepatologist introduced the product to PharmaQ sales force at the new facilities of Iasis Pharma in Koropi. Dr. Christos Kon. Zavos presented all the Updated Facts, Important Scientific Data & Newest Developments [...]
Qpain® is a new topical anti-inflammatory cutaneous solution, containing diclofenac sodium 1.5% w/w, indicated for the symptomatic relief of pain associated with osteoarthritis in superficial joints, including the knee. – Qpain® contains DMSO which enhances the absorption of diclofenac from the skin and reaches the focus of pain and inflammation directly. Ideal for those who cannot [...]
IASIS PHARMA is pleased to announce the Nitrofurantoin/IASIS oral susp. launching in the oral suspension formulation. This Innovative Pharmaceutical Form is a global market leader. This dosage form is Research and Development by IASIS PHARMA HELLAS S.A. Each 5ml of oral suspension Nitrofurantoin/IASIS oral susp. contains 25mg of Nitrofurantoin monohydrate which, according to international literature, [...]
IASIS PHARMA is pleased to announce the release of its new product ETROZAC®. ETROZAC® active substance is etoricoxib which is a selective cox-2 inhibitor. ETROZAC® is indicated for the relief of the symptoms of Osteoarthritis (OA), Rheumatoid Arthritis (RA), Ankylosing Spondylitis and the pain and symptoms of inflammation associated with Acute Gout. ETROZAC® is indicated for the [...]
IASIS PHARMA is pleased to announce the release of the new product Rami – Amlo plus® Rami – Amlo plus® is an original (prototype) fixed dose combination of Ramipril – Amlodipine -Hydrochlorothiazide Rami – Amlo plus® is indicated for the treatment of hypertension. Available in packs of 30 capsules, in a wide dosage range: Rami [...]
IASIS PHARMA has successfully launched COVED® to the Greek market. COVED® (Bisphosphonates, combinations) is a fixed dose combination of two active ingredients: Alendronic acid (as alendronate sodium trihydrate) (70mg) & Cholecalciferol (Vitamin D3) (5.600 I.U). COVED® 70 mg / 5,600 IU is indicated for the treatment of postmenopausal osteoporosis in women at risk of vitamin D [...]
IASIS PHARMA is pleased to announce the launch of the new 60 f.c. tabs packaging for GLUCOPLUS® 1.000mg (Metformin hydrochloride). Both GLUCOFREE® & GLUCOPLUS® (active ingredient: metformin hydrochloride) belong to the broader category of Oral Hypoglycemic Agents (OHAs) for the treatment of Type 2 Diabetes Mellitus (T2D) as first-line therapy. GLUCOFREE® is available in 850mg metformin hydrochloride, [...]
IASIS PHARMA, consistently aware of its responsibility to serve at the highest possible level both health care professionals and patients, introduces to the pharmaceutical market Sensibio® in 30 g. new package. Sensibio® 30 g. new package was launched to the market in order to complete Sensibio® 15 g., the well-established fixed combination of Fusidic acid (antibiotic) and [...]
